Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body weight and kidney function effects on prophylactic nadroparin anti-Xa levels in hospitalized adults
NL-OMON48903Phase 4Recruiting
- Sponsor
- Diakonessenhuis
- Start
- Nov 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nadroparin in venous thromboembolism (VTE), sponsored by Diakonessenhuis. Primary endpoints: Primary anti-Xa level at 4 hours, Body weight determinants of anti-Xa and 1 more. Started Nov 2018; status: recruiting.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON48903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48903.